After failure of first-line radiation, both kinds of salvage brachytherapy are equally effective

A group of researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reported in 2014 (see this link) on the outcomes of 42 patients with radio-recurrent prostate cancer treated with salvage high-dose-rate brachytherapy (sHDR-BT). The results were quite good — … READ MORE …

Brachy boost therapy should be reserved for unfavorable risk patients

The ASCENDE-RT trial showed that oncological outcomes were improved among both intermediate-risk and high-risk men who were treated with external beam radiation (EBRT) and a brachytherapy boost (LDR-BT) to the prostate and adjuvant androgen deprivation therapy (ADT) (see this link). … READ MORE …

Revised ASCO/CCO brachytherapy guidelines

The publication of the ASCENDE-RT clinical trial (discussed here) has led to a revision in the brachytherapy guidelines (available here) issued jointly by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO). The guidelines are for patients who choose radical therapy rather than active surveillance. … READ MORE …

Brachy boost: the gold standard for progression-free survival of high-risk prostate cancer

Several randomized clinical trials have established the superior oncological outcomes of the combination of external beam radiotherapy with a high-dose-rate brachytherapy boost (see this link). … READ MORE …

Is once ever enough (in prostate radiation therapy)?

When Jeff Demanes at the California Endocurietherapy Center, then in Oakland, CA, started doing high-dose-rate brachytherapy (HDR-BT) as a monotherapy (i.e., without any additional external beam therapy or hormone therapy), he arbitrarily chose a treatment schedule of 42 Gy delivered in six treatments or fractions. … READ MORE …

Brachytherapy alone is enough for favorable intermediate-risk patients

RTOG 0232 was a large clinical trial conducted to determine whether low-dose-rate brachytherapy (LDR-BT) alone was of equal benefit compared to external beam radiation therapy with a brachytherapy boost (EBRT + LDR-BT) in intermediate-risk patients. … READ MORE …

For very high-risk patients, EBRT + BT is superior to surgery or EBRT only

A retrospective analysis of oncological outcomes among modern-era patients with a Gleason score of 9 or 10 demonstrates a clear advantage to a combination of external beam radiation therapy (EBRT) with a brachytherapy (BT) boost to the prostate and short–term androgen deprivation therapy (ADT). … READ MORE …